Viewing Study NCT05973903


Ignite Creation Date: 2025-12-24 @ 7:34 PM
Ignite Modification Date: 2026-01-01 @ 7:59 AM
Study NCT ID: NCT05973903
Status: WITHDRAWN
Last Update Posted: 2024-12-04
First Post: 2023-07-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Sponsor: Tel Aviv Medical Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module